Literature DB >> 11744066

Allelic and somatic variations in the endogenous opioid system of humans.

P Mayer1, V Höllt.   

Abstract

People with a genetic predisposition for substance abuse have defects in genes for the opioid peptides and receptors. A high number of polymorphisms have been detected in the mu-opioid receptor, some of which result in pharmacological alterations. The opioid peptide proopiomelanocortin proved extraordinarily rich in mutations that often lead to severe phenotypical consequences. Prodynorphin displays a polymorphic regulation of transcription. Variants of the mu- and the delta-opioid receptor showed positive associations with opiate and/or alcohol addiction in some studies. However, these associations were weak, indicating a small contribution of the opioid system to these disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11744066     DOI: 10.1016/s0163-7258(01)00154-1

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  8 in total

1.  Genotype patterns that contribute to increased risk for or protection from developing heroin addiction.

Authors:  D A Nielsen; F Ji; V Yuferov; A Ho; A Chen; O Levran; J Ott; M J Kreek
Journal:  Mol Psychiatry       Date:  2008-01-15       Impact factor: 15.992

2.  Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction.

Authors:  Vadim Yuferov; David Fussell; K Steven LaForge; David A Nielsen; Derek Gordon; Ann Ho; Suzanne M Leal; Jurg Ott; Mary Jeanne Kreek
Journal:  Pharmacogenetics       Date:  2004-12

3.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

4.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.

Authors:  Cielito C Reyes-Gibby; Sanjay Shete; Trude Rakvåg; Samrat V Bhat; Frank Skorpen; Eduardo Bruera; Stein Kaasa; Pål Klepstad
Journal:  Pain       Date:  2006-12-06       Impact factor: 6.961

5.  Functional expression of opioid receptors and other human GPCRs in yeast engineered to produce human sterols.

Authors:  Björn D M Bean; Colleen J Mulvihill; Riddhiman K Garge; Daniel R Boutz; Olivier Rousseau; Brendan M Floyd; William Cheney; Elizabeth C Gardner; Andrew D Ellington; Edward M Marcotte; Jimmy D Gollihar; Malcolm Whiteway; Vincent J J Martin
Journal:  Nat Commun       Date:  2022-05-24       Impact factor: 17.694

Review 6.  Opioids: a review.

Authors:  Eric Chevlen
Journal:  Curr Pain Headache Rep       Date:  2003-02

7.  Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment.

Authors:  Imen Chatti; Jean-Baptiste Woillard; Amira Mili; Isabelle Creveaux; Ilhem Ben Charfeddine; Jihène Feki; Sarah Langlais; Leila Ben Fatma; Ali Saad; Moez Gribaa; Frédéric Libert
Journal:  Iran J Public Health       Date:  2017-12       Impact factor: 1.429

Review 8.  Advances in genetic studies of substance abuse in China.

Authors:  Yan Sun; Shiqiu Meng; Jiali Li; Jie Shi; Lin Lu
Journal:  Shanghai Arch Psychiatry       Date:  2013-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.